Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
Gilead Sciences, Inc. logo

NASDAQ · GILD

Gilead Sciences, Inc.

Healthcare · Drug Manufacturers - General

$150.11

Down-$0.78 (-0.52%)

Updated Sep 20, 2026, 9:38 AM

SID Score

7.5/10

Composite research score

Smart Money

44/100

Neutral

Market cap
152.89B
P/E ratio
18.89
Dividend yield
2.62%
52-week range
$116.88 – $157.29
Volume
16.42M
Avg. volume
7.34M

Price performance

GILD price history

1M range · 19 trading sessions · Daily adjusted prices

GILD closed at $150.11 after 19 trading sessions, up 2.30% for the selected period.

Last close
$150.11
Period change
+2.30%
Period low
$143.72
Period high
$151.22
Daily close
View OHLC price history
GILD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$150.56$153.23$149.57$150.1116.42M
Sep 17, 2026$148.775$151.04$146.8901$150.897.84M
Sep 16, 2026$146.58$149.30$146.12$147.685.19M
Sep 15, 2026$144.002$146.35$142.94$146.304.54M
Sep 14, 2026$144.26$146.75$143.71$146.414.92M
Sep 11, 2026$145.24$145.99$143.50$143.724.2M
Sep 10, 2026$145.07$145.9066$143.67$144.816.02M
Sep 9, 2026$145.46$147.68$145.00$145.654.58M
Sep 8, 2026$146.98$148.6491$145.45$146.646.08M
Sep 4, 2026$149.23$151.185$149.23$150.9956.18M
Sep 3, 2026$150.67$151.48$148.41$151.224.5M
Sep 2, 2026$150.00$152.55$148.83$149.614.92M
Sep 1, 2026$148.52$149.96$146.915$149.924.87M
Aug 31, 2026$144.23$147.22$143.175$146.346.59M
Aug 28, 2026$149.47$149.47$144.88$145.683.95M
Aug 27, 2026$147.30$149.105$146.01$148.865.01M
Aug 26, 2026$148.00$149.6199$147.004$148.095.26M
Aug 25, 2026$146.60$148.94$145.58$148.774.63M
Aug 24, 2026$145.93$146.835$144.59$146.746.18M

Latest GILD news

The latest Smart Investors Daily articles mentioning GILD.

Stock researchCompany · Overview

GILD research

Overview

Company profile and research snapshot.

Company profile

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$130.64
Implied upside
—
Analysts
16
GILD recent ratings
DateFirmRatingTarget
Sep 10, 2026HSBCBuy—
Aug 5, 2026RBC CapitalSector Perform—
Aug 5, 2026Cantor FitzgeraldOverweight—
Aug 5, 2026NeedhamBuy—
Jul 29, 2026BarclaysEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 18, 2026

Gilead Strengthens HIV Growth Platform with Expanded Latin America Access

Gilead Sciences, Inc. (NASDAQ:GILD) has reached an agreement with the Pan American Health Organization (PAHO) to expand access to its twice-yearly HIV-prevention drug lenacapavir across Latin America and the Caribbean. The agreement creates a regional procurement pathway through PAHO for 14 countries, including Brazil, Mexico, Argentina, Colombia and Peru, that were outside Gilead’s existing voluntary […]

Yahoo · Sep 17, 2026

Latin America’s PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF

MEXICO CITY, September 17, 2026--AIDS Healthcare Foundation (AHF), the world’s largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organization (PAHO) that could expand access to lenacapavir for HIV prevention in 14 countries across Latin America. The agreement represents a positive step toward expanding access in the region and a victory for civil society.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By